{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-027947","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.780653+00:00","generated_at":"2026-06-12T02:14:55.400225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bioventus Q2 2023 net sales $137.1M (-2.3% YoY); Adjusted EBITDA $28.2M (+26%); FY2023 guidance issued","bullets":["Net loss from continuing ops $4.7M ($0.06 EPS loss) vs $7.7M loss in Q2 2022, improved.","Adjusted EBITDA $28.2M, up 26.1% YoY; Non-GAAP EPS $0.14 vs $0.10.","FY2023 guidance: net sales $490-505M, adjusted EBITDA $75-80M, Non-GAAP EPS ($0.24)-($0.20).","Repaid $60.3M of term loan and revolver; net leverage ratio reduced to 4.33 from 5.50.","Closed sale of Wound Business for $31M in net proceeds, used to repay debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-027947","json":"https://secwatch.observer/filing/0001628280-23-027947.json","markdown":"https://secwatch.observer/filing/0001628280-23-027947.md","text":"https://secwatch.observer/filing/0001628280-23-027947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023027947/0001628280-23-027947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023027947/bvs-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:14:55.400225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c12998072fdd49c94924aedbdd473c84ca75fefb","claim":"Bioventus Inc. reported twelve months ending December 31, 2023 results: revenue $490 million to $505 million, EPS ($0.24) to ($0.20). Guidance initiated.","evidence_excerpt":"For the twelve months ending December 31, 2023, the Company expects: • Net sales of $490 million to $505 million • Adjusted EBITDA* of $75 million to $80 million • Non-GAAP EPS* of ($0.24) to ($0.20)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023027947/0001628280-23-027947-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve months ending December 31, 2023"},{"label":"Revenue","value":"$490 million to $505 million"},{"label":"EPS","value":"($0.24) to ($0.20)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"fd40406162ad93f2c4218bb7d106fb9f77b9c7d7","claim":"Bioventus Inc. reported three and six months ended July 1, 2023 results: revenue $137.1 million, net income $4.7 million, EPS $0.06. Guidance initiated.","evidence_excerpt":"a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: • Net Sales of $137.1 million, down $3.3 million, or 2.3%, year-over-year as reported (2.3% constant currency*), excluding revenues from divested assets, underlying organic sales decreased $0.5 million, or","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023027947/0001628280-23-027947-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six months ended July 1, 2023"},{"label":"Revenue","value":"$137.1 million"},{"label":"Net income","value":"$4.7 million"},{"label":"EPS","value":"$0.06"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}